Published in final edited form as:

Bioconjug Chem. 2015 August 19; 26(8): 1606–1612. doi:10.1021/acs.bioconjchem.5b00231.

A Bile Acid Conjugated DNA Chimera that Conditionally Inhibits Carbonic Anhydrase-II in the Presence of MicroRNA-21

Xiaozhu Chu^a, Cooper Battle^a, Nan Zhang^a, Gyan H. Aryal^a, Madhusoodanan Mottamal^b, and Janarthanan Jayawickramarajah^{a,*}

^aDepartment of Chemistry, Tulane University, 2015 Percival Stern Hall, New Orleans, Louisiana 70118, United States

^bRCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, Louisiana 70125, United States

Abstract

In order to tackle the issue of systemic toxicity in chemotherapy, there is a need to develop novel mechanisms for the activation of protein inhibitors using biomarkers over-expressed in cancer cells. Many current strategies focus on using cancer associated enzymes as a triggering agent for prodrugs. Herein, we detail an alternative approach that harnesses a microRNA (miR-21) that is overexpressed in cancers as the trigger that activates an inhibitor of human carbonic anhydrase-II (hCA-II). Specifically, we have developed a DNA-small molecule chimera (DC) composed of an hCA-II binding lithocholic acid amide (LAA) head-group that can transition from a rigid duplex state (that does not bind appreciably to hCA) to a single stranded conformation via a miR-21 trigger. The activated single-stranded DC can project the LAA head-group into the hCA-II active site and is a robust hCA-II inhibitor (K_i of 3.12 μ M). This work may spur research into developing new classes of cancer selective protein inhibitors.

Abstract

*Corresponding Author: jananj@tulane.edu.

§ **Supporting Information** Detailed synthesis and characterization of DCs, modeling, effect of linker length on the inhibitory ability of the DCs, and the effect of LNA bases on mismatch discrimination can be found in the supplementary information. This information is available free of charge via the Internet at <http://pubs.acs.org>.

Introduction

Conventional cancer therapeutics often exhibit decreased drug efficacy and significant systemic toxicity due to non-specific biodistribution. To achieve site selective drug action there has been much exploration of nanocarriers and cytotoxic small molecules conjugated to targeting ligands.^{1–9} A complementary strategy is to use prodrugs that are conditionally activated by molecules localized in cancer tissue.^{10–14} Harnessing such endogenous stimuli is an appealing route, *inter alia*, because—unlike external inputs—there is no requirement for specialized and expensive equipment. The major approach utilized for molecular activation of prodrugs via endogenous inputs is to exploit the covalent transformations afforded by tumor-associated enzymes.^{13–18} Although a salient strategy, for each disease-associated enzyme that is harnessed one needs to laboriously design and optimize the corresponding prodrug structure. Additionally, disease-associated enzymes often have isoforms present in healthy tissue and generating isoform selective agents remains a formidable challenge.^{19–21}

In contrast to enzymes, oligonucleotides (ONs) are informational and many cancer-associated ONs with unique sequences have been identified. Thus the development of pharmacophores that are activated by cancer-associated ONs is an attractive route for prodrug generation. In this regard, microRNAs (miRs) are especially important biomarkers because a single miR can regulate the translation of multiple unique mRNAs and therefore has a significant role in disease progression.^{22–24} In particular, miR-21 is a critical miR that promotes tumor development by inhibiting the translation of key tumor suppressor genes and hence is over-expressed in various cancers including breast, colon, prostate, and lung.²⁵ In addition, miR-21 over-expression is correlated with cancer aggressiveness/stage,^{26, 27} and drug resistance.²⁸

A number of elegant strategies for ON templated triggering of inactive molecules and protein-inhibitors have been reported.^{29–49} These systems have largely centered on DNA templation that leads to an intramolecular covalent reaction.^{29–35} However, an issue with this strategy is the need for specialized bio-orthogonal reactions (to minimize side reactions with reactive biomolecules). In addition, once activated such systems cannot be further controlled (i.e., they lack reversibility). A complementary approach is to use the molecular recognition and subsequent conformational changes of ONs that are tethered to protein recognition elements (such as nucleic acids, small molecules and peptides)^{36–41} to develop allosteric protein binders.^{42–49} To the best of our knowledge, there is no report of using such ON hybrids to inhibit a protein in conditional response to a cancer-associated miR.⁵⁰ With this article, we disclose a novel DNA-small molecule chimera (DC 1) system that can inhibit human carbonic anhydrase-II (hCA-II) upon activation by miR-21 (see Figure 1).

Results and Discussion

HCA-II was chosen as the target protein to be inhibited because it is a cytosolic member of a family of metalloenzymes (hCAs) that catalyze the conversion of CO₂ to bicarbonate ion and a proton. While bicarbonate is a substrate for critical biological pathways (including gluconeogenesis and nucleotide synthesis), the production of protons can lead to pH

changes. Both of these hCA based effects are thought to be important in providing tumors with a growth advantage over normal tissue.^{51, 52} Thus, hCA inhibitors are being actively pursued.⁵³ Although we are targeting hCA-II in this study, it is important to note that the potential cancer selectivity of this system lies in its ability to use miR-21 as the over-expressed cancer biomarker to specifically activate the inhibitor in tumor tissues.

The design and function of DC **1** is shown in Figure 1. DC **1** contains a bile acid head-group (specifically, a lithocholic acid amide, LAA) since bile acids are known to interact with hCA-II.^{54, 55} The LAA head-group was attached to the core ON domain via a short C3 linker. This linker length was specifically utilized since in the single stranded state DC **1** can project the LAA moiety into the conical and deep (15 Å) active site of hCA-II.^{56, 57} However, the function of DC **1** can be turned OFF by hybridization with a complementary guide sequence (ON **2**) because the rigid duplex in conjunction with the short linker prevents the optimal positioning of the LAA head-group into the active site.⁵⁸ Furthermore, ON **2** contains a non base-paired toehold and is fully complementary to miR-21. Hence, in the presence of miR-21 the DC **1**:ON **2** duplex is expected to disassemble resulting in the formation of the ON **2**:miR-21 duplex and single stranded DC **1** (which is able to effectively inhibit hCA-II). For the design of guide ON **2**, six locked nucleic acid (LNA)⁵⁹ residues were incorporated into the toehold region since LNA based ONs have superior hybridization capacity with RNA.⁶⁰

UV-visible spectroscopy and polyacrylamide gel electrophoresis (PAGE) were employed to probe the self-assembly characteristics of DC **1**. In particular, since hydrophobic molecule-conjugated ONs^{61–65} can potentially form micelles, we investigated whether a low concentration (1 µM) of DC **1** shows such aggregation behavior. As can be seen from inspection of Figure 2A, both DC **1** and the DC **1**:ON **2** duplex (at 1 µM concentrations) exhibit characteristic absorption profiles centered around 260 nm, and show near baseline absorption at long wavelengths—indicating a lack of aggregate-based scattering. Further, when DC **1** was analyzed by non-denaturing PAGE (Figure 3A, Lane 1) only a single, fast-moving band, corresponding to a single strand was observed. There was no indication of any slow migrating higher-order species. Taken together, these findings are consistent with no significant self-aggregation induced by the hydrophobic LAA head-group in the 1 µM regime.

Next, UV-vis derived thermal denaturation studies were performed on both the DC **1**:ON **2** and the miR-21:ON **2** duplexes (Figure 2B). These experiments clearly suggested that the latter duplex is significantly more thermally stable (T_m greater by 18 °C) and thus exposure to miR-21 should drive the disassembly of the DC **1**:ON **2** duplex. In order to probe this structural conversion process PAGE was employed (Figure 3A). Here it is evident that upon addition of one equivalent of miR-21, the preformed DC **1**:ON **2** duplex (Lane 4) disassembles leading to the miR-21:ON **2** duplex and single-stranded DC **1** (Lane 6). Fluorescence spectroscopy was also conducted to verify the miR-21 induced structure switching (Figure 3B). Here, an internal deoxycytidine residue (C7 from the 3' end) of DC **1** was replaced with the fluorescent cytidine analog pyrrolo-2'-deoxycytidine (pdC). The pdC containing strand DC **1F** should show strong fluorescence in a single-stranded, non-base paired, conformation. However, when hybridized with guide ON **2** the fluorescence is

expected to be quenched.⁶⁶ Moreover, addition of miR-21 should lead to recovery of fluorescence as the single stranded DC **1F** is regenerated. The fluorescence experiment (Figure 3C) commenced with the titration of ON **2** into a solution of 1 μ M of DC **1F**. After the addition of one equivalent of ON **2**, the fluorescence signal reached a plateau. Subsequently, miR-21 was titrated into the equimolar solution of DC **1F** and ON **2**. Importantly, when one equivalent of miR-21 relative to DC **1F** was added, the fluorescence is fully recovered indicating stoichiometric responsiveness. These fluorescence studies verified the miR-21 induced structure switching mechanism observed by PAGE.

Having demonstrated that miR-21 can induce the structure-switching of duplex **1:2** into single stranded DC **1**, we next investigated whether the single-stranded and duplex states of DC **1** showed differential binding to hCA-II via a solid-phase binding assay (see Figures 4A and 6). Briefly, hCA-II was immobilized on a solid *N*-hydroxysuccinimidyl-sepharose bead support and was exposed to the following three ON species (in 10 mM Tris, 0.1 M NaCl, pH 7.4 buffer) to test for their binding abilities to hCA-II: (a) single stranded DC **1**, (b) duplex **1:2**, and (c) a solution containing duplex **1:2** that was incubated with 1 equivalent of miR-21. After incubation of these ON samples with hCA-II (at 4 °C for 5 hr), each sample was separated into two equal portions and the incubation buffer removed via centrifugal filters. The first portion of resin stayed unwashed (thus all the added ONs are expected to be present). On the other hand, to the second aliquot was introduced competitive washing solutions (see experimental section for details) so that only the strongly interacting species would remain bound to hCA-II. Subsequently, both aliquots of resins were resuspended in water, overlaid with 50 μ l of mineral oil, and incubated at 90 °C for 30 min to denature hCA-II and release the bound ON species. After denaturation, the aqueous layers were analyzed by PAGE.

As shown in Figure 4B, for the un-washed aliquots (Lane 4-6), all the introduced ON species are observed. Not surprisingly, after competitive washing to remove the weak binders, the **2**:miR-21 duplex that lacks the hCA-II binding head group is not present on the gel as it was washed away (compare the missing slow migrating band on Lane 9 that is observed on Lane 6). Moreover, the DC **1:2** duplex also does not appear on the gel (compare the missing band on Lane 8 that is present on Lane 5) as it does not bind appreciably with hCA-II—since the double-stranded structure inhibits the LAA head-group from binding effectively with hCA-II. Indeed the only ON species that survived the washing step was the single-stranded DC **1** either when introduced by itself (Lane 7) or when released from duplex **1:2** by miR-21 (Lane 9). These results indicate that the miR-21 triggered formation of DC **1** leads to substantial binding of hCA-II while duplex **1:2** does not interact significantly with the protein.

We next probed, via a solution phase colorimetric assay, whether the esterase activity of hCA-II is differentially affected by the duplex and single-stranded states of DC **1**. Figure 5 shows the normalized initial reaction velocity versus inhibitor concentration. As expected, single stranded DC **1** inhibited the esterase activity of hCA-II with a K_i of 2.56 μ M. In marked contrast, no significant inhibitory activity was observed for duplex **1:2** under the same experimental conditions. Importantly, in the presence of miR-21, the sample containing inactive duplex **1:2** exhibits hCA-II inhibition that is similar to that of DC **1** by

itself (K_i value of 3.12 μM). Taken together, these results clearly demonstrate that the OFF state of DC **1** (i.e., duplex **1:2**) is activated by miR-21 thereby leading to a state that inhibits the hCA-II esterase function.

Conclusions

We have developed a single-stranded LAA modified DC-based inhibitor against hCA-II that can be deactivated using a guide LNA containing strand **2**. This OFF state is postulated to be a result of the short linker and the steric hindrance introduced by the rigid duplex structure. Strikingly, in the presence of miR-21, the guide strand forms a more stable duplex with miR-21, thereby triggering the activation of the single-stranded inhibitor. This is the first report of using a conformationally restrained protein inhibitor that is non-covalently triggered by a microRNA. The strategy described above is expected to be broadly applicable to prodrug development since the sequence of the core ON domain of the DC can be modified to target other cancer-associated miRs and the synthetic ligand can be interchanged to bind to alternative active sites of target proteins. In addition, because simple sequestration of miR-21, via duplex formation, can silence its oncogenic activity,^{68, 69} this strategy has the potential to be synergistic. We are currently investigating DC activity *in vivo* using cancer cell lines over-expressing miR-21.

Experimental Procedures

Unless specially noted all chemicals were obtained from Sigma-Aldrich. All core oligonucleotide (ON) sequences, except guide ON sequence **2**, were synthesized by the Keck Foundation Biotechnology Research Laboratory at Yale University using automated solid phase synthesis. LNA containing ON **2** was synthesized by Exiqon. The non-standard, modified phosphoramidites (pyrrolo dC, 5'-amino Modifier C3 TFA, 5'- amino Modifier C6 PDA, and 5'- amino Modifier C12) were purchased from Glen Research. All ONs were desalted with sephadex resin Microspin G-25 columns (GE Healthcare), and purified via a Varian Prostar reverse-phase HPLC system. The purified product was analyzed by Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) mass spectrometry using a Bruker Daltonics Autoflex III in reflector negative mode. All MALDI-TOF samples were prepared by mixing 3-hydroxypicolinic acid (HPA, 50 mg/ml in 1:1 water/acetonitrile), ammonium citrate (50 mg/ml in water), and ON at a 9:1:1 ratio. The concentrations of the ON stock solutions were determined by the use of UV spectrophotometry based on the molar extinction coefficient at 260 nm as determined by the nearest neighbor method. Fluorescence spectroscopy was conducted using a Varian Cary Eclipse Fluorescence spectrophotometer. The hCA-II inhibition assay was performed using a SpectraMax 190 microplate reader. Detailed syntheses of head groups and ON-conjugates can be found in the SI.

Thermal Denaturation

Thermal denaturation was followed by UV-Visible absorption changes at 260 nm. Melting temperatures (T_m) were determined by fitting the collected data to a Boltzmann sigmoidal function in OriginPro 9.1.

Gel Electrophoresis

The 14% polyacrylamide TBE gel was prepared by mixing 3.5 ml of 40% acrylamide solution, 1 ml of $1 \times$ TBE buffer, and 5.5 ml of water, followed by the addition of 50 μ l of 10% ammonium persulfate (APS) and 10 μ l of *N,N,N',N'*-tetramethylethylenediamine (TEMED). The gel-forming solution was stirred for a couple of seconds, and then poured between the glass plates and a comb was inserted to form the gel.

For single stranded ONs (DC 1, ON 2 and miR-21) the samples were prepared in 10 μ l of water with an ON concentration of 2 μ M. The duplex ON samples (DC 1:ON 2 and ON 2:miR-21) were prepared by incubating the two ONs (2 μ M for each) in 10 μ l of water at R.T. for 30 min. The structure switching sample was prepared by incubating DC 1 and ON 2 (2 μ M for each) in 10 μ l of water at R.T. for 30 min, then adding one equivalent of miR-21 and incubating the three ONs at R.T. for another 30 min. The samples then were applied onto the gel and subjected to electrophoresis at a constant voltage of 120 V for 1 hr with $1 \times$ TBE running buffer. After electrophoresis, the gel was visualized by ethidium bromide staining.

HCA-II Immobilization

1 ml of *N*-Hydroxysuccinimidyl-Sepharose® 4 Fast Flow slurry was placed in an Amicon® centrifugal filter (cutoff: 10K) and spun to remove isopropanol, followed by washing with (a) 3×2 ml of cold 1 mM HCl and (b) 2 ml of cold water. hCA-II was dissolved in 500 μ l of $1 \times$ PBS buffer pH 7.1 at a concentration of 16 μ M (hCA-II concentration was determined by UV-Vis spectrometry). The hCA-II solution was incubated with the beads at 4 °C overnight. After removing the coupling solution, the beads were capped using 600 μ l of 50 mM Tris-HCl buffer pH 8.3 for 3 hr. After extensive washing with 3×2 ml of 10 mM Tris-HCl, 1 M NaCl buffer, pH 7.4, the beads were stored in 650 μ l of 10 mM Tris-HCl, 0.1 M NaCl buffer, pH 7.4, at 4 °C.

Solid-Phase HCA-II Binding Assays

Three species were tested for their binding abilities to hCA-II: (a) single stranded inhibitor DC 1 (2 μ l of 0.1 mM in water), (b) DC 1:ON 2 duplex (formed by incubating 2 μ l of 0.1 mM DC 1 with one equivalent of ON 2 in water at R.T. for 30 min, total volume was 4 μ l), and (c) DC 1:ON 2:miR21 (formed by incubating 2 μ l of 0.1 mM DC 1 with 1 equivalent of ON 2 at R.T. for 30 min, followed by the addition of 1 equivalent of miR-21, and incubation for another 30 min; total volume was 6 μ l). Each of these samples (i.e., a, b, and c) was added to an eppendorf tube containing 80 μ l of a bead suspension conjugated with hCA-II, followed by addition of 10 mM Tris, pH 7.4, 0.1 M NaCl buffer to reach a final volume of 200 μ l.

The eppendorf tube was agitated at 4 °C for 5 hr, then the mixture was separated into two equal aliquots (100 μ l of each) and both were transferred to centrifugal filters (cutoff: 30K) to remove the incubation buffers (Figure 6). For comparison purposes, the first aliquot of dry resin stayed unwashed while the second aliquot was washed with a competitive series of solutions: (1) 400 μ l of 10 mM Tris, pH 7.4, 0.5 M NaCl, (2) 2×400 μ l of 10 mM Tris, pH 7.4, 0.1 M NaCl, and (3) 400 μ l of water. Both aliquots of dry resin were then resuspended in 30 μ l of water and overlaid with 50 μ l of mineral oil, followed by incubation at 90 °C for

30 min to denature hCA-II. After denaturation, the bottom aqueous solution was pipetted out and allowed to cool down to R.T. over a period of 30 min, then analyzed by PAGE as described above.

Solution Phase hCAII Inhibition Studies

The hCA-II inhibition assay was conducted by dissolving hCA-II in 50 mM Tris-sulfate pH 8.5, and incubating in a 96-well plate with a dilution series of inhibitors for 30 min at R.T. Subsequently, the reaction was initiated by adding substrate, *p*-nitrophenyl acetate (*p*-NPA). The UV-vis absorption change at 405 nm, corresponding to the production of *p*-nitrophenolate was recorded.

Normalization of the initial reaction velocity was performed by assigning a maximum value of 1 to the initial reaction velocity obtained from an hCA-II esterase activity assay in the absence of any inhibitor for each series of experiments. Specific initial reaction velocities in the presence of inhibitors in these studies were converted to proportions of this value (ranging from 0 to 1).

The normalized initial reaction velocity (V_0) was plotted against the corresponding inhibitor concentration (I), and the K_i (the dissociation constant of the enzyme-inhibitor complex) value was obtained by fitting, via non-linear regression, to equation (1)⁶⁷ below using Origin software. S is the final concentration of the substrate *p*-NPA, which is 1 mM.

$$\nu = \frac{V_{max} [S]}{[S] + K_m \left(1 + \frac{[I]}{K_i}\right)} \quad (1)$$

The Michaelis-Menten constant K_m and the V_{max} values (V_{max} is a maximal limit of the rate of an enzyme-catalyzed reaction and K_m is defined by the substrate concentration that gives a reaction rate equal to one-half the V_{max}) were first obtained for *p*-NPA hydrolysis catalyzed by hCA-II in the absence of inhibitors (See SI-5).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

We gratefully acknowledge the NIH for supporting both the experimental (grant R01GM097571 to J.J.) and modeling portions of this work (2G12MD007595). C.H.B thanks the NSF for a graduate fellowship.

REFERENCES

- (1). Lehner R, Wang X, Marsch S, Hunziker P. Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application. *Nanomedicine*. 2013; 9:742–57. [PubMed: 23434677]
- (2). Zhong Y, Meng F, Deng C, Zhong Z. Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy. *Biomacromolecules*. 2014; 15:1955–1969. [PubMed: 24798476]

- (3). Allen TM. Ligand-targeted therapeutics in anticancer therapy. *Nat. Rev. Cancer*. 2002; 2:750–63. [PubMed: 12360278]
- (4). Liu Q, Jin C, Wang Y, Fang X, Zhang X, Chen Z, Tan W. Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy. *NPG Asia Mater*. 2014; 6:e95.
- (5). Chari RVJ. Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs. *Acc. Chem. Res*. 2008; 41:98–107. [PubMed: 17705444]
- (6). Song L, Ho VHB, Chen C, Yang Z, Liu D, Chen R, Zhou D. Efficient, pH-Triggered Drug Delivery Using a pH-Responsive DNA-Conjugated Gold Nanoparticle. *Adv. Healthc. Mater*. 2013; 2:275–280. [PubMed: 23184521]
- (7). Blum AP, Kammeyer JK, Rush AM, Callmann CE, Hahn ME, Gianneschi NC. Stimuli-Responsive Nanomaterials for Biomedical Applications. *J. Am. Chem. Soc*. 2015; 137:2140–2154. [PubMed: 25474531]
- (8). Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, Merkel TJ, Luthi AJ, Patel PC, Cutler JJ, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. *Science Translational Medicine*. 2013; 5:209ra152/1–209ra152/12. 12.
- (9). Ryu J-H, Chacko RT, Jiwanich S, Bickerton S, Babu RP, Thayumanavan S. Self-Cross-Linked Polymer Nanogels: A Versatile Nanoscopic Drug Delivery Platform. *J. Am. Chem. Soc*. 2010; 3:2–10.
- (10). Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. *Curr. Med. Chem*. 2008; 15:1802–1826. [PubMed: 18691040]
- (11). Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, Savolainen J. Prodrugs: design and clinical applications. *Nat. Rev. Drug Discov*. 2008; 7:255–70. [PubMed: 18219308]
- (12). Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. *Pharmacol. Reports*. 2013; 65:1–14.
- (13). Cui J, Li S. Inhibitors and Prodrugs Targeting CYP1: A Novel Approach in Cancer Prevention and Therapy. *Curr. Med. Chem*. 2014; 21:519–552. [PubMed: 24083611]
- (14). Tietze LF, Schmuck K. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. *Curr. Pharm. Des*. 2011; 17:3527–3547. [PubMed: 22074425]
- (15). Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of anticancer prodrugs. *Pharmacol. Rev*. 2004; 56:53–102. [PubMed: 15001663]
- (16). Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. *Cancer Chemother. Pharmacol*. 2000; 45:291–7. [PubMed: 10755317]
- (17). Tanaka A, Fukuoka Y, Morimoto Y, Honjo T, Koda D, Goto M, Maruyama T. Cancer-cell death induced by the intracellular self-assembly of an enzyme-responsive supramolecular gelator. *J. Am. Chem. Soc*. 2015; 137:770–775. [PubMed: 25521540]
- (18). Chien M-P, Carlini AS, Hu D, Barback CV, Rush AM, Hall DJ, Orr G, Gianneschi NC. Enzyme-Directed Assembly of Nanoparticles in Tumors Monitored by in Vivo Whole Animal Imaging and ex Vivo Super-Resolution Fluorescence Imaging. *J. Am. Chem. Soc*. 2013; 135:18710–18713. [PubMed: 24308273]
- (19). Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem. Rev*. 2012; 112:4421–68. [PubMed: 22607219]
- (20). Agrawal A, Romero-Perez D, Jacobsen J. a, Villarreal FJ, Cohen SM. Zinc-binding groups modulate selective inhibition of MMPs. *ChemMedChem*. 2008; 3:812–20. [PubMed: 18181119]
- (21). Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? *Cancer Lett*. 2009; 280:211–21. [PubMed: 19289255]
- (22). Ambros V. The functions of animal microRNAs. *Nature*. 2004; 431:350–355. [PubMed: 15372042]
- (23). Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell*. 2004; 116:281–297. [PubMed: 14744438]
- (24). Hammond SM. MicroRNA therapeutics: a new niche for antisense nucleic acids. *Trends Mol. Med*. 2006; 12:99–101. [PubMed: 16473043]

- (25). Krichevsky AM, Gabriely G. MiR-21: a small multi-faceted RNA. *J. Cell. Mol. Med.* 2009; 13:39–53. [PubMed: 19175699]
- (26). Calin, G. a; Croce, CM. MicroRNA signatures in human cancers. *Nat. Rev. Cancer.* 2006; 6:857–66. [PubMed: 17060945]
- (27). Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. *Nat. Rev. Cancer.* 2006; 6:259–69. [PubMed: 16557279]
- (28). Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. *Mol. Cancer Ther.* 2010; 9:3126–36. [PubMed: 20940321]
- (29). Okamoto A, Tanabe K, Inasaki T, Saito I. Phototriggered drug release from functionalized oligonucleotides by a molecular beacon strategy. *Angew. Chem. Int. Ed. Engl.* 2003; 42:2502–4. [PubMed: 12800170]
- (30). Janssen BMG, Lempens EHM, Olijve LLC, Voets IK, van Dongen JLJ, de Greef TFA, Merckx M. Reversible blocking of antibodies using bivalent peptide–DNA conjugates allows protease-activatable targeting. *Chem. Sci.* 2013; 4:1442.
- (31). Shibata A, Ito Y, Abe H. RNA-templated molecule release induced protein expression in bacterial cells. *Chem. Commun.* 2013; 49:270–2.
- (32). Ma Z, Taylor J-S. Nucleic acid-triggered catalytic drug release. *Proc. Natl. Acad. Sci.* 2000; 97:11159–11163. [PubMed: 11027325]
- (33). Rothlingshofer M, Gorska K, Winssinger N. Nucleic Acid-Templated Energy Transfer Leading to a Photorelease Reaction and its Application to a System Displaying a Nonlinear Response. *J. Am. Chem. Soc.* 2011; 133:18110–18113. [PubMed: 22004511]
- (34). Erben A, Grossmann TN, Seitz O. DNA-triggered synthesis and bioactivity of proapoptotic peptides. *Angew. Chem. Int. Ed. Engl.* 2011; 50:2828–32. [PubMed: 21387498]
- (35). Li X, Liu DR. DNA-templated organic synthesis: nature's strategy for controlling chemical reactivity applied to synthetic molecules. *Angew. Chem. Int. Ed. Engl.* 2004; 43:4848–70. [PubMed: 15372570]
- (36). Kim Y, Cao Z, Tan W. Molecular assembly for high-performance bivalent nucleic acid inhibitor. *Proc. Natl. Acad. Sci.* 2008; 105:5664–9. [PubMed: 18398007]
- (37). Melkko S, Zhang Y, Dumelin CE, Scheuermann J, Neri D. Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library. *Angew. Chemie, Int. Ed.* 2007; 46:4671–4674.
- (38). Eberhard H, Diezmann F, Seitz O. DNA as a molecular ruler: interrogation of a tandem SH2 domain with self-assembled, bivalent DNA-peptide complexes. *Angew. Chem. Int. Ed. Engl.* 2011; 50:4146–50. [PubMed: 21455916]
- (39). Tagore DM, Sprinz KI, Fletcher S, Jayawickramarajah J, Hamilton AD. Protein recognition and denaturation by self-assembling fragments on a DNA quadruplex scaffold. *Angew. Chem. Int. Ed. Engl.* 2007; 46:223–5. [PubMed: 17136788]
- (40). Simon P, Dueymes C, Fontecave M, Décout J-L. DNA detection through signal amplification by using NADH: flavin oxidoreductase and oligonucleotide-flavin conjugates as cofactors. *Angew. Chem. Int. Ed. Engl.* 2005; 44:2764–7. [PubMed: 15772944]
- (41). Diezmann F, Seitz O. DNA-guided display of proteins and protein ligands for the interrogation of biology. *Chem. Soc. Rev.* 2011; 40:5789–801. [PubMed: 21589953]
- (42). Röglin L, Ahmadian MR, Seitz O. DNA-controlled reversible switching of peptide conformation and bioactivity. *Angew. Chem. Int. Ed. Engl.* 2007; 46:2704–7. [PubMed: 17330908]
- (43). Portela C, Albericio F, Eritja R, Castedo L, Mascareñas JL. ds-Oligonucleotide-Peptide Conjugates Featuring Peptides from the Leucine-Zipper Region of Fos as Switchable Receptors for the Oncoprotein Jun. *ChemBioChem.* 2007; 8:1110–1114. [PubMed: 17516573]
- (44). Dittmer WU, Reuter A, Simmel FC. A DNA-based machine that can cyclically bind and release thrombin. *Angew. Chem. Int. Ed. Engl.* 2004; 43:3550–3. [PubMed: 15293242]
- (45). Saghatelian A, Guckian KM, Thayer DA, Ghadiri MR. DNA Detection and Signal Amplification via an Engineered Allosteric Enzyme. *J. Am. Chem. Soc.* 2003; 125:344–345. [PubMed: 12517141]
- (46). Harris DC, Chu X, Jayawickramarajah J. DNA-small molecule chimera with responsive protein-binding ability. *J. Am. Chem. Soc.* 2008; 130:14950–14951. [PubMed: 18855469]

- (47). Harris DC, Saks BR, Jayawickramarajah J. Protein-binding molecular switches via host-guest stabilized DNA hairpins. *J. Am. Chem. Soc.* 2011; 133:7676–9. [PubMed: 21534531]
- (48). Battle C, Chu X, Jayawickramarajah J. Oligonucleotide-Based Systems for Input-Controlled and Non-Covalently Regulated Protein-Binding. *Supramol. Chem.* 2013; 25:37–41.
- (49). Zhou C, Yang Z, Liu D. Reversible Regulation of Protein Binding Affinity by a DNA Machine. *J. Am. Chem. Soc.* 2012; 134:1416–1418. [PubMed: 22229476]
- (50). Recently an elegant report was published wherein miR-21 is used as a trigger to release doxorubicin from mesoporous silica coated nanoparticles Zhang P, Cheng F, Zhou R, Cao J. DNA-Hybrid-Gated Multifunctional Mesoporous Silica Nanocarriers for Dual-Targeted and MicroRNA-Responsive Controlled Drug Delivery. *Angew. Chemie.* 2014; 53:2371–5. In contrast, the current study investigates an allosteric prodrug activation mechanism instead of a nanocarrier based drug release strategy.
- (51). Thiry A, Dogné J-M, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. *Trends Pharmacol. Sci.* 2006; 27:566–73. [PubMed: 16996620]
- (52). Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. *Curr. Pharm. Des.* 2008; 14:685–698. [PubMed: 18336315]
- (53). Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. *Med. Res. Rev.* 2003; 23:146–189. [PubMed: 12500287]
- (54). Boone CD, Tu C, McKenna R. Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II. *Acta Crystallogr. D. Biol. Crystallogr.* 2014; 70:1758–63. [PubMed: 24914985]
- (55). Milov DE, Jou WS, Shireman RB, Chun PW. The effect of bile salts on carbonic anhydrase. *Hepatol.* 1992; 15:288–296.
- (56). Eriksson AE, Jones TA, Liljas A. Refined structure of human carbonic anhydrase II at 2.0 Å resolution. *Proteins Struct. Funct. Genet.* 1988; 4:274–282. [PubMed: 3151019]
- (57). Avvaru BS, Kim CU, Sippel KH, Gruner SM, Agbandje-McKenna M, Silverman DN, McKenna R. A short, strong hydrogen bond in the active site of human carbonic anhydrase II. *Biochemistry.* 2010; 49:249–51. [PubMed: 20000378]
- (58). For the effect of linker length on DC binding to hCA-II, see SI-2 (for hCA-II inhibition assays) and SI-3 (for modeling studies).
- (59). Singh SK, Nielsen P, Koshkin AA, Wengel J. LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. *Chem. Commun.* 1998:455–456.
- (60). Thomsen R, Nielsen PS, Jensen TH. Dramatically improved RNA in situ hybridization signals using LNA-modified probes. *RNA.* 2005; 11:1745–1748. [PubMed: 16177135]
- (61). Gryaznov SM, Lloyd DH. Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions. *Nucleic Acids Res.* 1993; 21:5909–5915. [PubMed: 8290352]
- (62). Bleczinski CF, Richert C. Steroid–DNA Interactions Increasing Stability, Sequence-Selectivity, DNA/RNA Discrimination, and Hypochromicity of Oligonucleotide Duplexes. *J. Am. Chem. Soc.* 1999; 121:10889–10894.
- (63). Rosemeyer H. Nucleolipids: Natural Occurrence, Synthesis, Molecular Recognition, and Supramolecular Assemblies as Potential Precursors of Life and Bioorganic Materials. *Chem. Biodiversity.* 2005; 2:977–1063.
- (64). Laing BM, Barrow-Laing L, Harrington M, Long EC, Bergstrom DE. Properties of Double-Stranded Oligonucleotides Modified with Lipophilic Substituents. *Bioconjugate Chem.* 2010; 21:1537–1544.
- (65). Serien D, Grimm C, Liebscher J, Herrmann A, Arbuzova A. DNA-controlled aggregation of virus like particles - mimicking a tetherin-like mechanism. *New J. Chem.* 2014; 38:5181–5185.
- (66). Zhang X, Wadkins RM. DNA hairpins containing the cytidine analog pyrrolo-dC: structural, thermodynamic, and spectroscopic studies. *Biophys. J.* 2009; 96:1884–1891. [PubMed: 19254547]
- (67). Brandt RB, Laux JE, Yates SW. Calculation of inhibitor K_i and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. *Biochem. Med. Metab. Biol.* 1987; 37:344–9. [PubMed: 3606895]

- (68). Yang M, Mattes J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. *Pharmacol. Ther.* 2008; 117:94–104. [PubMed: 17928059]
- (69). Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with “antagomirs”. *Nature.* 2005; 438:685–9. [PubMed: 16258535]

Figure 1.

An illustration depicting miR-21 induced activation of a DC based hCA-II inhibitor. (i) A toe-hold containing duplex is formed between DC 1 and an LNA guide sequence 2. This duplex sterically hinders the lithocholic acid amide head-group (red arrow head) from binding to the active site of hCA-II. (ii) In response to miR-21, which is fully complementary to ON 2, the more stable miR-21:ON 2 duplex is formed, thereby releasing the single-stranded DC 1. (iii) The activated and flexible single-stranded DC 1 is a strong binder of hCA-II. Inset: Summary of the key ON sequences used in this study. Note: The sequence in blue for ON 2 depicts the LNA residues.

Figure 2.

A) UV-visible spectra of DC1 and DC1:ON2 duplex at 20 °C. B) Thermal denaturation curves of DC1:ON2 and ON2:miR-21 duplexes. All spectra were collected in a 100 μ M Tris-NaCl buffer at 7.1 pH with 1 μ M ON strand concentrations.

Figure 3.

(A) PAGE illustrating miR21-induced structure switching of DC **1**. Lanes 1-5: ON single strand or duplex controls. Lane 1, DC **1**; Lane 2, ON **2**; Lane 3, miR-21; Lane 4, duplex **1:2**; Lane 5, duplex miR-21:**2**. Lane 6: The structure switching experiment: DC **1** + ON **2** (incubated for 30 min) followed by addition of miR-21 (incubated for 30 min). (B) Schematic of the pdC based fluorescence assay. (i) The fluorescence is quenched when pdC is base-paired with guanine in the DC **1F:2** duplex, and then (ii) recovered upon addition of miR-21 when single-stranded **1F** is released via the formation of the more stable miR-21:**2** duplex. (C) Results of the fluorescence assay. Left: Fluorescence quenching of **1F** upon hybridization with ON **2**. Right: Fluorescence recovery of **1F** induced by miR-21. Excitation $\lambda = 345$ nm and emission $\lambda = 450$ nm; these experiments were conducted in 0.2 M NaCl, 0.1 M Tris, pH = 7.4, buffer.

Figure 4.

(A) hCA-II binding assay. (i) The three tested ON species were incubated with hCA-II immobilized on a solid support. (ii) An aliquot of the unwashed sample (containing all non-specifically/specifically bound ONs) was denatured with heat and run on the gel. (iii) An aliquot of sample washed with a competitive buffer (to select for the strong binding ON species) was denatured with heat and run on the gel. (B) PAGE results of the hCA-II solid phase binding assay. Lanes 1-3: ON controls. Lane 1, DC 1; Lane 2, ONs 1/2; Lane 3, ONs 1/2/miR-21. Lanes 4-6: Unwashed aliquots. Lane 4, DC 1; Lane 5, ONs 1/2; Lane 6, ONs 1/2/miR-21. Lanes 7-9: Aliquots washed with competitive buffer. Lane 7, DC 1; Lane 8, ONs 1/2; Lane 9, ONs 1/2/miR-21.

Figure 5. hCA-II inhibition profiles. The concentrations of hCA-II and *p*-NPA were 124 nM and 1 mM, respectively.

Figure 6.
Illustration of the procedure for the solid-phase hCA-II binding assay.